Latest & greatest articles for statin

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on statin or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on statin and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for statin

141. High-sensitivity C-reactive protein levels combined to low-density lipoprotein cholesterol levels may be a drug evaluation biomarker for patients with chronic kidney disease receiving statins alone or in combination with ezetimibe: a two-stage network met

High-sensitivity C-reactive protein levels combined to low-density lipoprotein cholesterol levels may be a drug evaluation biomarker for patients with chronic kidney disease receiving statins alone or in combination with ezetimibe: a two-stage network met Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. CRD bears no responsibility or liability for the content

2017 PROSPERO

142. Hydrophilic versus lipophilic statins for primary prevention of cardiovascular disease in elderly people: An adjusted indirect comparison meta-analysis

Hydrophilic versus lipophilic statins for primary prevention of cardiovascular disease in elderly people: An adjusted indirect comparison meta-analysis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email salutation (e.g. "Dr Smith

2017 PROSPERO

143. Evaluating the Efficacy, Safety and Cost-Effectiveness of Antihypertensive Drugs, Statins and Combination Cardiovascular Drug Therapies in South Asia: A Systematic Review and Meta-Analysis

Evaluating the Efficacy, Safety and Cost-Effectiveness of Antihypertensive Drugs, Statins and Combination Cardiovascular Drug Therapies in South Asia: A Systematic Review and Meta-Analysis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites

2017 PROSPERO

144. The impact of statins on clinical outcomes in patients with a previous stroke: a systematic review and meta-analysis

The impact of statins on clinical outcomes in patients with a previous stroke: a systematic review and meta-analysis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email salutation (e.g. "Dr Smith" or "Joanne") for correspondence

2017 PROSPERO

145. Prescribing appropriateness in the use of statins for the management of LDL cholesterol in diabetic patients in US healthcare settings

Prescribing appropriateness in the use of statins for the management of LDL cholesterol in diabetic patients in US healthcare settings Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email salutation (e.g. "Dr Smith" or "Joanne

2017 PROSPERO

146. Efficacy and safety of statins added to antipsychotics for schizophrenia: a systematic review and meta-analysis

Efficacy and safety of statins added to antipsychotics for schizophrenia: a systematic review and meta-analysis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email salutation (e.g. "Dr Smith" or "Joanne") for correspondence

2017 PROSPERO

147. Is statins associated with risk of clostidium difficile infection and outcomes?

Is statins associated with risk of clostidium difficile infection and outcomes? Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email salutation (e.g. "Dr Smith" or "Joanne") for correspondence: Organisation web address: Timing

2017 PROSPERO

148. Effects of alternate-day versus daily dosing of statin therapy on lipid profile: a systematic review and meta-analysis of randomized controlled trials

Effects of alternate-day versus daily dosing of statin therapy on lipid profile: a systematic review and meta-analysis of randomized controlled trials Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email salutation (e.g. "Dr Smith

2017 PROSPERO

149. Statin therapy and the risk of recurrent venous thromboembolism

Statin therapy and the risk of recurrent venous thromboembolism Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email salutation (e.g. "Dr Smith" or "Joanne") for correspondence: Organisation web address: Timing and effect measures

2017 PROSPERO

150. A meta-analysis of randomized controlled trials assessing the impact of statins with and without ezetimibe on cardiovascular outcomes in the chronic kidney disease spectrum

A meta-analysis of randomized controlled trials assessing the impact of statins with and without ezetimibe on cardiovascular outcomes in the chronic kidney disease spectrum Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email salutation

2017 PROSPERO

151. Cholesterol: slightly higher risk of type 2 diabetes with all statins

Cholesterol: slightly higher risk of type 2 diabetes with all statins Prescrire IN ENGLISH - Spotlight ''Cholesterol: slightly higher risk of type 2 diabetes with all statins'', 1 January 2017 {1} {1} {1} | | > > > Cholesterol: slightly higher risk of type 2 diabetes with all statins Spotlight Every month, the subjects in Prescrire’s Spotlight. 100 most recent :  |   |   |   |   |   |   |   |   |  Spotlight Cholesterol (...) : slightly higher risk of type 2 diabetes with all statins Several large-scale studies have revealed an increased risk of type 2 diabetes in patients taking a statin. Statins are widely used to lower cholesterol, in the hope of reducing the risk of premature death and major cardiovascular events (myocardial infarction, ischaemic stroke). A review has been carried out of 13 studies which included patient follow-up for at least one year. Some 91,000 non-diabetic participants were monitored for 4 years

2017 Prescrire

152. Patterns and predictors of adherence to statin therapy among older patients: a systematic review

Patterns and predictors of adherence to statin therapy among older patients: a systematic review Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email salutation (e.g. "Dr Smith" or "Joanne") for correspondence: Organisation web address

2017 PROSPERO

153. Statins for primary and secondary prevention of cardiovascular disease

Statins for primary and secondary prevention of cardiovascular disease

2017 DynaMed Plus

157. Comparative efficacy of statins for prevention of contrast-induced acute kidney injury in patients with chronic kidney disease: evidence from network meta-analysis of randomized controlled trials

Comparative efficacy of statins for prevention of contrast-induced acute kidney injury in patients with chronic kidney disease: evidence from network meta-analysis of randomized controlled trials Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. CRD bears no responsibility or liability for the content of this registration record, any associated files or external

2017 PROSPERO

158. Effect of statins on stroke recurrence and clinical outcomes as a secondary prevention strategy for patients with previous ischemic stroke or intracranial hemorrhage

Effect of statins on stroke recurrence and clinical outcomes as a secondary prevention strategy for patients with previous ischemic stroke or intracranial hemorrhage Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email salutation (e.g

2017 PROSPERO

159. A systematic review and meta-analysis to compare reported rates of statin-associated muscle symptoms, under blinded and open-label conditions

A systematic review and meta-analysis to compare reported rates of statin-associated muscle symptoms, under blinded and open-label conditions Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email salutation (e.g. "Dr Smith" or "Joanne

2017 PROSPERO

160. Effect of ezetimibe addition versus statin therapy alone on coronary atheroma regression measured by intravascular ultrasound: a systematic review and meta-analysis

Effect of ezetimibe addition versus statin therapy alone on coronary atheroma regression measured by intravascular ultrasound: a systematic review and meta-analysis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email salutation (e.g

2017 PROSPERO